Do you take any precautions in planning PMRT for patients who had taxane-induced pneumonitis?  

Assuming the patient has N2-3 disease, would you consider omitting IMN? What other techniques would you consider to limit lung exposure?



Answer from: Radiation Oncologist at Community Practice